1. Reciprocal repression between P53 and TCTP
- Author
-
Salvatore Pece, Jessika Wynendaele, Jean-Christophe Marine, Daniela Tosoni, Johan Hoebeke, Rajesh Vyas, Ivan Nicola Colaluca, Robert Amson, Pier Paolo Di Fiore, Sylvie Rodrigues-Ferreira, Giuseppe Viale, Alexandra Lespagnol, Adam Telerman, Giovanni Mazzarol, Olivier Chaloin, Laboratoire de Biologie et de Pharmacologie Appliquée (LBPA), École normale supérieure - Cachan (ENS Cachan)-Centre National de la Recherche Scientifique (CNRS), Università degli Studi di Milano [Milano] (UNIMI), CHU Pontchaillou [Rennes], Division of Pathology and Laboratory Medicine, European Institute of Oncology [Milan] (ESMO), Università degli Studi di Milano [Milano] (UNIMI)-European Institute of Oncology [Milan] (ESMO), Institut Cochin (IC UM3 (UMR 8104 / U1016)), Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Immunologie et chimie thérapeutiques (ICT), Cancéropôle du Grand Est-Centre National de la Recherche Scientifique (CNRS), Centre de Génétique Humaine, Université Catholique de Louvain = Catholic University of Louvain (UCL), Università degli studi di Milano [Milano], Università degli studi di Milano [Milano]-European Institute of Oncology [Milan] (ESMO), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université Catholique de Louvain (UCL), and European Institute of Oncology
- Subjects
[SDV]Life Sciences [q-bio] ,Apoptosis ,Breast Neoplasms ,Nerve Tissue Proteins ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Haploinsufficiency ,[SDV.BC]Life Sciences [q-bio]/Cellular Biology ,Biology ,General Biochemistry, Genetics and Molecular Biology ,Mice ,03 medical and health sciences ,0302 clinical medicine ,Translationally-controlled tumor protein ,Biomarkers, Tumor ,Animals ,Humans ,[SDV.BBM]Life Sciences [q-bio]/Biochemistry, Molecular Biology ,Promoter Regions, Genetic ,030304 developmental biology ,Feedback, Physiological ,Mice, Knockout ,Regulation of gene expression ,Mice, Inbred BALB C ,[SDV.GEN]Life Sciences [q-bio]/Genetics ,0303 health sciences ,Gene knockdown ,Mammary tumor ,Ubiquitination ,Membrane Proteins ,Tumor Protein, Translationally-Controlled 1 ,Proto-Oncogene Proteins c-mdm2 ,General Medicine ,HCT116 Cells ,Prognosis ,3. Good health ,Gene Expression Regulation, Neoplastic ,030220 oncology & carcinogenesis ,Proteolysis ,Cancer cell ,Neoplastic Stem Cells ,NUMB ,biology.protein ,Cancer research ,Mdm2 ,Female ,Translationally controlled tumour protein ,Tumor Suppressor Protein p53 ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology - Abstract
International audience; Screening for genes that reprogram cancer cells for the tumor reversion switch identified TCTP (encoding translationally controlled tumor protein) as a crucial regulator of apoptosis. Here we report a negative feedback loop between P53 and TCTP. TCTP promotes P53 degradation by competing with NUMB for binding to P53-MDM2-containing complexes. TCTP inhibits MDM2 auto-ubiquitination and promotes MDM2-mediated ubiquitination and degradation of P53. Notably, Tctp haploinsufficient mice are sensitized to P53-dependent apoptosis. In addition, P53 directly represses TCTP transcription. In 508 breast cancers, high-TCTP status associates with poorly differentiated, aggressive G3-grade tumors, predicting poor prognosis (P < 0.0005). Tctp knockdown in primary mammary tumor cells from ErbB2 transgenic mice results in increased P53 expression and a decreased number of stem-like cancer cells. The pharmacological compounds sertraline and thioridazine increase the amount of P53 by neutralizing TCTP's action on the MDM2-P53 axis. This study links TCTP and P53 in a previously unidentified regulatory circuitry that may underlie the relevance of TCTP in cancer.
- Published
- 2011